| 000 | 01837 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517082247.0 | ||
| 264 | 0 | _c20170109 | |
| 008 | 201701s 0 0 eng d | ||
| 022 | _a1399-3062 | ||
| 024 | 7 |
_a10.1111/tid.12516 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAlhefzi, M | |
| 245 | 0 | 0 |
_aGuillain-Barré syndrome associated with resistant cytomegalovirus infection after face transplantation. _h[electronic resource] |
| 260 |
_bTransplant infectious disease : an official journal of the Transplantation Society _cApr 2016 |
||
| 300 |
_a288-92 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article; Research Support, U.S. Gov't, Non-P.H.S. | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aCytomegalovirus _xdrug effects |
| 650 | 0 | 4 |
_aCytomegalovirus Infections _xcomplications |
| 650 | 0 | 4 | _aDrug Resistance, Multiple, Viral |
| 650 | 0 | 4 |
_aFacial Transplantation _xadverse effects |
| 650 | 0 | 4 |
_aGanciclovir _xanalogs & derivatives |
| 650 | 0 | 4 |
_aGuillain-Barre Syndrome _xetiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunocompromised Host |
| 650 | 0 | 4 |
_aImmunoglobulins, Intravenous _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aValganciclovir |
| 650 | 0 | 4 | _aViral Load |
| 650 | 0 | 4 | _aViremia |
| 700 | 1 | _aAycart, M A | |
| 700 | 1 | _aBueno, E M | |
| 700 | 1 | _aKueckelhaus, M | |
| 700 | 1 | _aFischer, S | |
| 700 | 1 | _aSnook, R J | |
| 700 | 1 | _aSharfuddin, A A | |
| 700 | 1 | _aHadad, I | |
| 700 | 1 | _aMalla, P | |
| 700 | 1 | _aAmato, A A | |
| 700 | 1 | _aPomahac, B | |
| 700 | 1 | _aMarty, F M | |
| 773 | 0 |
_tTransplant infectious disease : an official journal of the Transplantation Society _gvol. 18 _gno. 2 _gp. 288-92 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/tid.12516 _zAvailable from publisher's website |
| 999 |
_c25765150 _d25765150 |
||